Chance Favors the Prepared Mind - From Serendipity to Rational Drug Design

References

• Roberts R. M. Serendipity. Accidental discoveries in science. John Wiley & Sons, New York 1989
   Google Scholar
• Horace Walpole's Correspondence, S. L. Lewis. Yale University Press, New Haven 1937; 31 Vols
   Google Scholar
• Remer T. G. Serendipity and the three princes. From the Peregrinaggio of 1557. University of Oklahoma Press, Norman 1965, Translated from the book Peregrinaggio di tre giovani, figliuoli del re di Serendippo; tradotto dalla lingua persiana in lingua italiana do M. Christoforo Armeno. Venice, Michele Tramezzino, 1557
   Google Scholar
• Sneader W. Drug prototypes and their exploitation. John Wiley & Sons, Chichester 1996
   Google Scholar
• Burger A. A guide to the chemical basis of drug design. John Wiley & Sons, New York 1983
   Google Scholar
• de Stevens G. Serendipity and structured research in drug discovery, Progr. Drug Res. 1986; 30: 189–203
   Google Scholar
• Restak R. M. Receptors. Bantam Books, New York 1994
   Google Scholar
• Böhm H.-J., Klebe G., Kubinyi H. Wirkstoffdesign. Spektrum Akademischer Verlag, Heidelberg 1996
   Google Scholar
• Sternbach L. H. The benzodiazepine story. Progr. Drug Res. 1978; 22: 229–266
   PubMedGoogle Scholar
• Burger's medicinal chemistry and drug discovery. Volume 1: Principles and practice, M. E. Wolff. John Wiley & Sons, New York 1995
   Google Scholar
• Sternweis P. C., Gilman A. G. Aluminum: a requirement for activation of the regulatory component of adenylate cyclase by fluoride. Proc. Natl. Acad. Sci. USA 1982; 79: 4888–4891
   PubMed Web of Science ®Google Scholar
• Sondek J., Lambright D. G., Noel J. P., Hamm H. E., Sigler P. B. GTPase mechanism of Gproteins from the 1.7-Å crystal structure of transducin α. GDP. AIF4-. Nature 1994; 372: 276–279
   PubMed Web of Science ®Google Scholar
• Goodford P. J. Drug design by the method of receptor fit. J. Med. Chem. 1984; 27: 557–564
   Web of Science ®Google Scholar
• Ganellin C. R., Roberts S. M. Medicinal chemistry. The role of organic chemistry in drug researchSecond Edition. Academic Press, London 1993
   Google Scholar
• Greer J., Erickson J. W., Baldwin J. J., Varney M. D. Application of the three-dimensional structures of protein target molecules in structure-based drug design. J. Med. Chem. 1994; 37: 1035–1054
   PubMed Web of Science ®Google Scholar
• Vacca J. P., Condra J. H. Clinically effective HIV-1 protease inhibitors. Drug Discovery today 1997; 2: 6–18
   Web of Science ®Google Scholar
• von Itzstein M., Wu W. Y., Kok G. B., Pegg M. S., Dyason J. C., Jin B., Phan T. V., Smythe M. L., White H. F., Oliver S. W., Colman P. M., Varghese J. N., Ryan D. M., Woods J. M., Bethell R. C., Hotham V. J., Cameron J. M., Penn C. R. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993; 363: 418–423
   PubMed Web of Science ®Google Scholar
• von Itzstein M., Dyason J. C., Oliver S. W., White H. F., Wu W. Y., Kok G. B., Pegg M. S. A study of the active site of influenza virus sialidase: an approach to the rational design of novel anti-influenza drugs. J. Med. Chem. 1996; 39: 388–391
   PubMed Web of Science ®Google Scholar
• Chand P., Babu Y. S., Bantia S., Chu N., Cole L. B., Kotian P. L., Laver W. G., Montgomery J. A., Pathak V. P., Petty S. L., Shrout D. P., Walsh D. A., Walsh G. M. Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design. J. Med. Chem. 1997; 40: 4030–4052
   PubMed Web of Science ®Google Scholar
• Kim C. U., Lew W., Williams M. A., Liu H., Zhang L., Swaminathan S., Bischofberger N., Chen M. S., Mendel D. B., Tai C. Y., Laver W. G., Stevens R. C. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J. Am. Chem. Soc. 1997; 119: 681–690
   PubMed Web of Science ®Google Scholar
• The design of drugs to macromolecular targets, C. R. Beddell. John Wiley & Sons, Chichester 1992
   Google Scholar
• The practice of medicinal chemistry, C. G. Wermuth. Academic Press, London 1996
   Google Scholar
• Bohacek R. S., McMartin C., Guida W. C. The art and practice of structure-based drug design: a molecular modeling perspective. Med. Res. Rev. 1996; 16: 3–50
   PubMed Web of Science ®Google Scholar
• Babine R. E., Bender S. L. Molecular recognition of proteinligand complexes: applications to drug design. Chem. Rev. 1997; 97: 1359–1472
   PubMed Web of Science ®Google Scholar
• Structure-based drug design, P. Veerapandian. Marcel Dekker, Inc., New York 1997
   Google Scholar
• Structure-based drug design, K. Gubernator, H.-J. Böhm. Wiley-VCH, Weinheim 1998
   Google Scholar
• Evans B. E., Bock M. G., Rittle K. E., DiPardo R. M., Whitter W. L., Veber D. F., Anderson P. S., Freidinger R. M. Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin. Proc. Natl. Acad. Sci. USA 1986; 83: 4918–4922
   PubMed Web of Science ®Google Scholar
• Samanen J. GPIIb/IIIa antagonists. Annu. Rep. Med. Chem. 1996; 31: 91–100
   Web of Science ®Google Scholar
• Engleman V. W., Kellogg M. S., Rogers T. E. Cell adhesion integrins as pharmaceutical targets. Annu. Rep. Med. Chem. 1996; 31: 191–200
   Web of Science ®Google Scholar
• Samanen J. M., Ali F. E., Barton L. S., Bondinell W. E., Burgess J. L., Callahan J. F., Calvo R. R., Chen W., Chen L., Erhard K., Feuerstein G., Heys R., Hwang S. M., Jakas D. R., Keenan R. M., Ku T. W., Kwon C., Lee C. P., Miller W. H., Newlander K. A., Nichols A., Parker M., Peishoff C. E., Rhodes G., Ross S., Shu A., Simpson R., Takata D., Yellin T. O., Uzsinskas I., Venslavsky J. W., Yuan C. K., Huffman W. F. Potent, selective, orally active 3-oxo-1,4-benzodiazepine GPIIb/IIIa integrin antagonists. J. Med. Chem. 1996; 39: 4867–4870
   PubMed Web of Science ®Google Scholar
• Keenan R. M., Miller W. H., Kwon C., Ali F. E., Callahan J. F., Calvo R. R., Hwang S. M., Kopple K. D., Peishoff C. E., Samanen J. M., Wong A. S., Yuan C. K., Huffman W. F. Discovery of potent nonpeptide vitronectin receptor (αvβ3) antagonists. J. Med. Chem. 1997; 40: 2289–2292
   PubMed Web of Science ®Google Scholar
• Gulliver's Travels. Motte, London 1726, published anonymously, Swift, J. Gulliver's Travels. Part III. A voyage to Laputa, Balnibarbi, Glubbdubdrib, Luggnagg and Japan, Chapter 5. Penguin Classics, Penguin Books Ltd., London, 1985, p. 223–231
   Google Scholar
• Dolle R. E. Discovery of enzyme inhibitors through combinatorial chemistry. Molecular Diversity 1996; 2: 223–236
   Web of Science ®Google Scholar
• Cowley P. M., Rees D. C. Applications of solid-phase synthesis to drug discovery. Curr. Med. Chem. 1997; 4: 211–227
   Web of Science ®Google Scholar
• Bone R., Salemme F. R. The integration of structure-based design and directed combinatorial chemistry for new pharmaceutical discovery. Structure-based drug design, P. Veerapandian. Marcel Dekker, New York 1997; 525–539
   Google Scholar
• Myers P. L. Will combinatorial chemistry deliver real medicines?. Curr. Opin. Biotechnol. 1997; 8: 701–707
   PubMed Web of Science ®Google Scholar
• Shuker S. B., Hajduk P. J., Meadows R. P., Fesik S. W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996; 274: 1531–1534
   PubMed Web of Science ®Google Scholar
• Hajduk P. J., Meadows R. P., Fesik S. W. Discovering high-affinity ligands for proteins. Science 1997; 278: 497–499
   PubMed Web of Science ®Google Scholar
• Hajduk P. J., Sheppard G., Nettesheim D. G., Olejniczak E. T., Shuker S. B., Meadows R. P., Steinman D. H., Carrera G. M., Jr., Marcotte P. A., Severin J., Walter K., Smith H., Gubbins E., Simmer R., Holzman T. F., Morgan D. W., Davidsen S. K., Summers J. B., Fesik S. W. Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR. J. Am. Chem. Soc. 1997; 119: 5818–5827
   Web of Science ®Google Scholar
• Müller K. De novo design. Persp. Drug Discov. Design 1995; 3: 1–209
   Google Scholar
• Höltje H. D., Folkers G. Molecular modeling. Basic principles and applications. VCH, Weinheim 1996
   Google Scholar
• Bamborough P., Cohen F. E. Modeling protein-ligand complexes. Curr. Opin. Struct. Biol. 1996; 6: 236–241
   PubMed Web of Science ®Google Scholar
• Böhm H.-J. Computational tools for structure-based ligand design. Prog. Biophys. Molec. Biol. 1996; 66: 197–210
   PubMed Web of Science ®Google Scholar
• Böhm H.-J. Current computational tools for de novo ligand design. Curr. Opin. Biotechnol. 1996; 7: 433–436
   PubMed Web of Science ®Google Scholar
• Lengauer T., Rarey M. Computational methods for biomolecular docking. Curr. Opin. Struct. Biol. 1996; 6: 402–406
   PubMed Web of Science ®Google Scholar
• Marrone T. J., Briggs J. M., McCammon J. A. Structure-based drug design: computational advances. Annu. Rev. Pharmacol. Toxicol. 1997; 37: 71–90
   PubMed Web of Science ®Google Scholar
• Parrill A. Recent advances in computer-aided drug design methods. Exp. Opin. Ther. Patents 1997; 7: 937–945
   Web of Science ®Google Scholar
• Lemmen C., Lengauer T. Time-efficient flexible superposition of medium-sized molecules. J. Comput.-Aided Mol. Design 1997; 11: 357–368, See also http://cartan.gmd.de/flex-bin/FlexS
   PubMed Web of Science ®Google Scholar
• Rarey M., Kramer B., Lengauer T., Klebe G. A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol. 1996; 261: 470–489, See also http://cartan.gmd.de/flex-bin/FlexX
   PubMed Web of Science ®Google Scholar
• Makino S., Kuntz I. D. Automated flexible ligand docking method and its application for database search. J. Comput. Chem. 1997; 18: 1812–1825
   Web of Science ®Google Scholar
• Westhead D. R., Clark D. E., Murray C. W. A comparison of heuristic search algorithms for molecular docking. J. Comput.-Aided Mol. Design 1997; 11: 203–228
   Web of Science ®Google Scholar
• Dixon J. S. Evaluation of the CASP2 docking section. Proteins 1997; 27(Suppl. 1)198–204, and following articles in this special issue on the “Second Meeting on the Critical Assessment of Techniques for Protein Structure Prediction” (CASP2), Asilomar, CA, USA, December 13–16, 1996
   Google Scholar
• Böhm H.-J. The computer program LUDI: a new method for the de novo design of enzyme inhibitors. J. Comput.-Aided Mol. Design 1992; 6: 61–78
   PubMed Web of Science ®Google Scholar
• Böhm H.-J. LUDI: rule-based automatic design of new substituents for enzyme inhibitor leads. J. Comput.-Aided Mol. Design 1992; 6: 593–606
   PubMed Web of Science ®Google Scholar
• Böhm H.-J. Ligand design. 3D QSAR in drug design. Theory, methods and applications, H. Kubinyi. ESCOM Science Publishers B. V., Leiden 1993; 386–405
   Google Scholar
• Böhm H.-J. Towards the automatic design of synthetically accessible protein ligands: peptides, amides and peptidomimetics. J. Comput.-Aided Mol. Design 1996; 10: 265–272
   PubMed Web of Science ®Google Scholar
• Böhm H.-J. (1997) Combinatorial docking. Computer-assisted lead finding and optimization (Proceedings of the 11th European symposium on quantitative structure-activity relationships, Lausanne, 1996, H. van de Waterbeemd, B. Testa, G. Folkers. Verlag Helvetica Chimica Acta and VCH, Basel and Weinheim, 123–133
   Google Scholar
• Caflisch A., Karplus M. Computational combinatorial chemistry for de novo ligand design: review and assessment. Persp. Drug Discov. Design 1995; 3: 51–84
   Google Scholar
• Caflisch A., Ehrhardt C. Structure-based combinatorial ligand design. Structure-based drug design, P. Veerapandian. Marcel Dekker, New York 1997; 541–558
   Google Scholar
• Hubbard R. E. Can drugs be designed?. Curr. Opin. Biotechnol. 1997; 8: 696–700
   PubMed Web of Science ®Google Scholar
• Graul A. I. The year's new drugs. Drug News Perspect 1998; 11: 15–32
   PubMedGoogle Scholar
• 3D QSAR in drug design. Volume 2. Ligand-protein interactions and molecular similarity, H. Kubinyi, G. Folkers, Y. C. Martin. Kluwer Academic Publishers, Dordrecht 1998
   Google Scholar
• Mattos C., Ringe D. Multiple binding modes. 3D-QSAR in drug design. Theory, methods and applications, H. Kubinyi. ESCOM Science Publishers B. V., Leiden 1993; 226–254
   Google Scholar
• Meyer E. F., Botos I., Scapozza L., Zhang D. Backward binding and other structural surprises. Persp. Drug. Discov. Design 1995; 3: 168–195
   Google Scholar
• Böhm H.-J., Klebe G. What can we learn from molecular recognition in protein-ligand complexes for the design of new drugs?. Angew. Chem. Int. Ed. Engl. 1996; 35: 2589–2614
   Web of Science ®Google Scholar
• Kubinyi H. Similarity and dissimilarity: a medicinal chemist's view. 3D QSAR in drug design. Ligand-protein interactions and molecular similarity, H. Kubinyi, G. Folkers, Y. C. Martin. Kluwer Academic Publishers, Dordrecht 1998; 225–252
   Google Scholar
• Zinkernagel R. M. Lecture “Immunität gegen Viren”. presented at the Symposium “Pharmazie. Die Wissenschaft vom Arzneimittel” of the German and Swiss Pharmaceutical Societies, ZurichSwitzerland, October, 02–051997
   Google Scholar